The Immunohistochemistry Facility (IHC) provides support for basic research in cellular structure/function, as well as translational research in clinical applications and molecular medicine. The IHC serves the faculty in the Cancer Research Center by providing state-of-the-art immunohistochemistry and immunofluorescence technology, as well as primary processing of tissues for histologic sectioning and routine hematoxylin and eosin staining. The Facility has three goals: (1) to provide routine histologic and immunohistochemical services in a timely manner using cutting-edge technology and expertise;(2) to evaluate and implement new techniques and stains for development; and (3) to provide education. Routine services include processing of tissues to paraffin blocks, paraffin and frozen sections, routine hematoxylin and eosin staining, and a variety of immunohistochemical and immunofluorescent stains utilizing state-of-the-art instrumentation and a broad array of available characterized antibodies. Technology and application development is nurtured by a close relationship with Cancer Research Center investigators who produce novel antibodies and reagents in the course of their research. The laboratory also is an educational resource for investigators and graduate students who are unfamiliar with handling animal tissues and/or with the techniques used by the Core Facility;this activity frequently requires consultation, one-on-one training sessions, and advice on protocol development. Overall usage of the IHC has increased significantly since the 2001 CCSG submission with significant recent expansion;the number of projects performed in 2006 totaled three times the number performed the previous year. Currently, over 35 peer-reviewed UCCRC investigators across all six Scientific Programs routinely utilize the IHC, totaling 70% of Facility usage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-35
Application #
8105368
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
35
Fiscal Year
2010
Total Cost
$85,227
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications